Asia Deal Watch: India’s Encube Targeted As Private Equity Interest In CDMOs Grows
Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.
You may also be interested in...
How Integrity Due Diligence In Lifesciences Is Changing Post COVID-19
Senior Kroll executive outlines sharp shifts in scope of integrity and reputational due diligence in the healthcare and life sciences sector post COVID-19, with investors now seeking "very micro" insights of target firms.
Sosei Heptares Turns To AI In GPCR-Focused Drug Discovery Pact
Sosei Heptares hopes to create transformative therapeutics for immune diseases by combining its GPCR structure-based drug design and early development capabilities with InveniAI's already validated AI-based platform, its head of new target identification tells Scrip.
Indian Leaders Begin Unique Collaboration On Molnupiravir
Major Indian pharmaceutical companies including Cipla, Dr Reddy’s, Emcure, Sun and Torrent have entered into a first-of-its-kind collaboration to jointly sponsor, supervise and monitor the clinical trial of the investigational oral anti-viral drug molnupiravir to fight against COVID-19 in India.